-
Price Momentum
LLY is trading near the top of its 52-week range and above its 200-day simple moving average.
-
Price change
The price of LLY shares has increased $33.67 since the market last closed. This is a 3.90% rise.
-
Closed at $896.53.
The stock has since dropped $3.73 in after-hours trading.
Key terms
About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
-
Market cap: $815.73B
A market capitalization above $200 billion places LLY in the mega-capitalization category.
Key terms
Ad Feedback
Smart score
Latest LLY news
Yesterday
9:02pm ET
Major Shareholder Cashes Out Big on Eli Lilly Stock!
Yesterday
3:06pm ET
Eli Lilly (LLY) to Build $3 Billion European Plant to Manufacture Weight-Loss Pill
Yesterday
1:45pm ET
BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
Yesterday
1:10pm ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Avantor (AVTR)
Yesterday
11:30am ET
Eli Lilly’s New Study on Brenipatide: A Potential Game-Changer in Smoking Cessation
Yesterday
8:35am ET
Eli Lilly to build new $3B facility in Katwijk, the Netherlands
Oct 31, 2025
9:07pm ET
Eli Lilly’s Earnings Call: Robust Growth and Strategic Wins
Oct 31, 2025
3:23pm ET
Eli Lilly (LLY) Says Weight-Loss Pill a Candidate for Fast-Track Approval
Oct 31, 2025
11:35am ET
Eli Lilly price target raised to $950 from $900 at BofA
Oct 31, 2025
11:15am ET
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
Oct 31, 2025
8:40am ET
Eli Lilly price target raised to $985 from $925 at Cantor Fitzgerald
Oct 31, 2025
8:18am ET
Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Oct 31, 2025
8:17am ET
BMO Capital Keeps Their Buy Rating on Eli Lilly & Co (LLY)
Oct 31, 2025
7:47am ET
Citi Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Oct 31, 2025
6:43am ET
Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Celldex (CLDX) and Illumina (ILMN)
Oct 31, 2025
1:19am ET
Eli Lilly Reports Strong Q3 2025 Growth
Oct 30, 2025
12:30pm ET
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Oct 30, 2025
12:01pm ET
Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
Oct 30, 2025
9:07am ET
Morning Movers: Alphabet, Eli Lilly rise following quarterly results
Oct 30, 2025
8:57am ET
Video: Megacap tech trio, trade truce set tone
Oct 30, 2025
8:35am ET
Eli Lilly & Co (LLY) Gets a Buy from TD Cowen
Oct 30, 2025
8:05am ET
Options Volatility and Implied Earnings Moves Today, October 30, 2025
Oct 30, 2025
7:30am ET
LLY Earnings: Eli Lilly Stock Soars Thanks to Massive Year-Over-Year Growth
Oct 30, 2025
7:17am ET
Eli Lilly reports Q3 EPS $7.02, consensus $5.89
Oct 30, 2025
7:16am ET
Eli Lilly raises FY25 EPS view to $23.00-$23.70 from $21.75-$23.00
Oct 30, 2025
6:05am ET
FDA moves to accelerate biosimilar development, lower drug costs
Oct 30, 2025
4:00am ET
These Are the Stocks Reporting Earnings Today – October 30, 2025
Oct 29, 2025
3:05pm ET
Notable companies reporting before tomorrow’s open
Oct 29, 2025
2:33pm ET
Eli Lilly (LLY) Invests $1.2 Billion in Puerto Rico Manufacturing Plant
Oct 29, 2025
2:30pm ET
AI Daily: Nvidia becomes first $5 trillion company as AI boom powers rally
Oct 29, 2025
2:05pm ET
Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Nov 01, 2020
10:23am ET
ELI LILLY INVESTOR NOTICE
Oct 29, 2020
8:33pm ET
Eli Lilly Investor Alert
Oct 21, 2020
12:24pm ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm
Oct 19, 2020
9:15pm ET
Eli Lilly Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
Oct 18, 2020
10:08am ET
Eli Lilly Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
Oct 16, 2020
3:02pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm
Oct 15, 2020
8:12pm ET
Eli Lilly Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
Oct 14, 2020
7:43pm ET
Eli Lilly Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm
LLY Financials
-
Total revenue: $45.04B (1Y), $17.60B (Q3)
Total Revenue increased 32.0% since last year and increased 13.13% since last quarter.
-
Net income: $10.59B (1Y), $5.58B (Q3)
Net Income increased 102.08% since last year and held flat since last quarter.
-
Earnings per share: $11.71 (1Y), $6.21 (Q3)
EPS increased 101.91% since last year and held flat since last quarter.
Key terms
Ad Feedback
LLY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LLY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
-
How competitors are chosen
LLY's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $815.73B
A market capitalization above $200 billion places LLY in the mega-capitalization category.
